FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012017615> ?p ?o ?g. }

• W2012017615 endingPage "e778" @default.
• W2012017615 startingPage "e778" @default.
• W2012017615 abstract "Withania somnifera or Ashwagandha is a medicinal herb of Ayurveda. Though the extract and purified molecules, withanolides, from this plant have been shown to have different pharmacological activities, their effect on bone formation has not been studied. Here, we show that one of the withanolide, withaferin A (WFA) acts as a proteasomal inhibitor (PI) and binds to specific catalytic β subunit of the 20S proteasome. It exerts positive effect on osteoblast by increasing osteoblast proliferation and differentiation. WFA increased expression of osteoblast-specific transcription factor and mineralizing genes, promoted osteoblast survival and suppressed inflammatory cytokines. In osteoclast, WFA treatment decreased osteoclast number directly by decreasing expression of tartarate-resistant acid phosphatase and receptor activator of nuclear factor kappa-B (RANK) and indirectly by decreasing osteoprotegrin/RANK ligand ratio. Our data show that in vitro treatment of WFA to calvarial osteoblast cells decreased expression of E3 ubiquitin ligase, Smad ubiquitin regulatory factor 2 (Smurf2), preventing degradation of Runt-related transcription factor 2 (RunX2) and relevant Smad proteins, which are phosphorylated by bone morphogenetic protein 2. Increased Smurf2 expression due to exogenous treatment of tumor necrosis factor α (TNFα) to primary osteoblast cells was decreased by WFA treatment. This was corroborated by using small interfering RNA against Smurf2. Further, WFA also blocked nuclear factor kappa-B (NF-kB) signaling as assessed by tumor necrosis factor stimulated nuclear translocation of p65-subunit of NF-kB. Overall data show that in vitro proteasome inhibition by WFA simultaneously promoted osteoblastogenesis by stabilizing RunX2 and suppressed osteoclast differentiation, by inhibiting osteoclastogenesis. Oral administration of WFA to osteopenic ovariectomized mice increased osteoprogenitor cells in the bone marrow and increased expression of osteogenic genes. WFA supplementation improved trabecular micro-architecture of the long bones, increased biomechanical strength parameters of the vertebra and femur, decreased bone turnover markers (osteocalcin and TNFα) and expression of skeletal osteoclastogenic genes. It also increased new bone formation and expression of osteogenic genes in the femur bone as compared with vehicle groups (Sham) and ovariectomy (OVx), Bortezomib (known PI), injectible parathyroid hormone and alendronate (FDA approved drugs). WFA promoted the process of cortical bone regeneration at drill-holes site in the femur mid-diaphysis region and cortical gap was bridged with woven bone within 11 days of both estrogen sufficient and deficient (ovariectomized, Ovx) mice. Together our data suggest that WFA stimulates bone formation by abrogating proteasomal machinery and provides knowledge base for its clinical evaluation as a bone anabolic agent." @default.
• W2012017615 created "2016-06-24" @default.
• W2012017615 creator A5004203270 @default.
• W2012017615 creator A5010244816 @default.
• W2012017615 creator A5014236716 @default.
• W2012017615 creator A5028638112 @default.
• W2012017615 creator A5030014884 @default.
• W2012017615 creator A5032880706 @default.
• W2012017615 creator A5043617968 @default.
• W2012017615 creator A5050125768 @default.
• W2012017615 creator A5052412003 @default.
• W2012017615 creator A5054221385 @default.
• W2012017615 creator A5067644651 @default.
• W2012017615 creator A5081244725 @default.
• W2012017615 creator A5083558391 @default.
• W2012017615 date "2013-08-22" @default.
• W2012017615 modified "2023-10-14" @default.
• W2012017615 title "Withaferin A: a proteasomal inhibitor promotes healing after injury and exerts anabolic effect on osteoporotic bone" @default.
• W2012017615 cites W1520951628 @default.
• W2012017615 cites W1922207530 @default.
• W2012017615 cites W1964483457 @default.
• W2012017615 cites W1967267975 @default.
• W2012017615 cites W1967502057 @default.
• W2012017615 cites W1968425609 @default.
• W2012017615 cites W1969001131 @default.
• W2012017615 cites W1971157583 @default.
• W2012017615 cites W1972135859 @default.
• W2012017615 cites W1973526333 @default.
• W2012017615 cites W1973621507 @default.
• W2012017615 cites W1976475315 @default.
• W2012017615 cites W1979560551 @default.
• W2012017615 cites W1986179699 @default.
• W2012017615 cites W1986227530 @default.
• W2012017615 cites W1987176983 @default.
• W2012017615 cites W1992422220 @default.
• W2012017615 cites W2004190331 @default.
• W2012017615 cites W2015725833 @default.
• W2012017615 cites W2020615661 @default.
• W2012017615 cites W2020641663 @default.
• W2012017615 cites W2028627202 @default.
• W2012017615 cites W2029697567 @default.
• W2012017615 cites W2036008223 @default.
• W2012017615 cites W2039839937 @default.
• W2012017615 cites W2042028347 @default.
• W2012017615 cites W2045805069 @default.
• W2012017615 cites W2065697878 @default.
• W2012017615 cites W2076408697 @default.
• W2012017615 cites W2076624423 @default.
• W2012017615 cites W2082190072 @default.
• W2012017615 cites W2082552678 @default.
• W2012017615 cites W2085627522 @default.
• W2012017615 cites W2089858094 @default.
• W2012017615 cites W2094071522 @default.
• W2012017615 cites W2096234941 @default.
• W2012017615 cites W2108595411 @default.
• W2012017615 cites W2110149781 @default.
• W2012017615 cites W2117539495 @default.
• W2012017615 cites W2121551386 @default.
• W2012017615 cites W2121680389 @default.
• W2012017615 cites W2127114287 @default.
• W2012017615 cites W2128447822 @default.
• W2012017615 cites W2130766059 @default.
• W2012017615 cites W2131350538 @default.
• W2012017615 cites W2132572939 @default.
• W2012017615 cites W2137388847 @default.
• W2012017615 cites W2146696914 @default.
• W2012017615 cites W2153817682 @default.
• W2012017615 cites W2157445945 @default.
• W2012017615 cites W2158866825 @default.
• W2012017615 cites W2159403469 @default.
• W2012017615 cites W2161882340 @default.
• W2012017615 cites W2168384602 @default.
• W2012017615 cites W2256257390 @default.
• W2012017615 cites W2412367416 @default.
• W2012017615 cites W4244095134 @default.
• W2012017615 doi "https://doi.org/10.1038/cddis.2013.294" @default.
• W2012017615 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3763455" @default.
• W2012017615 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23969857" @default.
• W2012017615 hasPublicationYear "2013" @default.
• W2012017615 type Work @default.
• W2012017615 sameAs 2012017615 @default.
• W2012017615 citedByCount "98" @default.
• W2012017615 countsByYear W20120176152013 @default.
• W2012017615 countsByYear W20120176152014 @default.
• W2012017615 countsByYear W20120176152015 @default.
• W2012017615 countsByYear W20120176152016 @default.
• W2012017615 countsByYear W20120176152017 @default.
• W2012017615 countsByYear W20120176152018 @default.
• W2012017615 countsByYear W20120176152019 @default.
• W2012017615 countsByYear W20120176152020 @default.
• W2012017615 countsByYear W20120176152021 @default.
• W2012017615 countsByYear W20120176152022 @default.
• W2012017615 countsByYear W20120176152023 @default.
• W2012017615 crossrefType "journal-article" @default.
• W2012017615 hasAuthorship W2012017615A5004203270 @default.
• W2012017615 hasAuthorship W2012017615A5010244816 @default.
• W2012017615 hasAuthorship W2012017615A5014236716 @default.
• W2012017615 hasAuthorship W2012017615A5028638112 @default.

• next